← Back to Treatments
🏅 FDA Orphan Designation

Vyvgart Hytrulo

EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)

Manufacturer: argenx US

Indicated for:
Chronic inflammatory demyelinating polyneuropathyOrphanTransient neonatal myasthenia gravisOrphanOBSOLETE: Channelopathy due to a neuronal acetylcholine receptor defect

FDA-Approved Indications (3)

treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive ( 1 ) chronic inflammatory demyelinating polyneuropathy (CIDP) ( 1 )

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.